nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—PTGS2—pancreatic cancer	0.236	1	CbGaD
Naproxen—AKR1C3—Doxorubicin—pancreatic cancer	0.12	0.223	CbGbCtD
Naproxen—UGT2B7—Epirubicin—pancreatic cancer	0.0704	0.131	CbGbCtD
Naproxen—UGT1A1—Erlotinib—pancreatic cancer	0.0656	0.122	CbGbCtD
Naproxen—UGT1A1—Irinotecan—pancreatic cancer	0.0592	0.11	CbGbCtD
Naproxen—ALB—Erlotinib—pancreatic cancer	0.0249	0.0463	CbGbCtD
Naproxen—CYP2C8—Tamoxifen—pancreatic cancer	0.0226	0.0421	CbGbCtD
Naproxen—ALB—Irinotecan—pancreatic cancer	0.0225	0.0418	CbGbCtD
Naproxen—CYP1A2—Dacarbazine—pancreatic cancer	0.022	0.0409	CbGbCtD
Naproxen—ALB—Fluorouracil—pancreatic cancer	0.0215	0.0401	CbGbCtD
Naproxen—CYP2C8—Erlotinib—pancreatic cancer	0.0192	0.0358	CbGbCtD
Naproxen—CYP1A2—Tamoxifen—pancreatic cancer	0.0175	0.0326	CbGbCtD
Naproxen—CYP2C8—Fluorouracil—pancreatic cancer	0.0167	0.031	CbGbCtD
Naproxen—CYP2C9—Tamoxifen—pancreatic cancer	0.0158	0.0293	CbGbCtD
Naproxen—CYP1A2—Erlotinib—pancreatic cancer	0.0149	0.0277	CbGbCtD
Naproxen—CYP1A2—Fluorouracil—pancreatic cancer	0.0129	0.024	CbGbCtD
Naproxen—CYP2C9—Fluorouracil—pancreatic cancer	0.0116	0.0216	CbGbCtD
Naproxen—Indomethacin—CXCL8—pancreatic cancer	0.000631	0.139	CrCbGaD
Naproxen—Ketoprofen—CXCL8—pancreatic cancer	0.000505	0.111	CrCbGaD
Naproxen—Ibuprofen—CXCL8—pancreatic cancer	0.000497	0.109	CrCbGaD
Naproxen—Nabumetone—PTGS2—pancreatic cancer	0.000491	0.108	CrCbGaD
Naproxen—Carprofen—PTGS2—pancreatic cancer	0.000468	0.103	CrCbGaD
Naproxen—Indomethacin—PPARG—pancreatic cancer	0.000436	0.0958	CrCbGaD
Naproxen—Ibuprofen—PPARG—pancreatic cancer	0.000343	0.0755	CrCbGaD
Naproxen—Suprofen—PTGS2—pancreatic cancer	0.000289	0.0636	CrCbGaD
Naproxen—Fenoprofen—PTGS2—pancreatic cancer	0.000249	0.0548	CrCbGaD
Naproxen—Indomethacin—PTGS2—pancreatic cancer	0.000184	0.0405	CrCbGaD
Naproxen—Flurbiprofen—PTGS2—pancreatic cancer	0.000163	0.0358	CrCbGaD
Naproxen—Ketoprofen—PTGS2—pancreatic cancer	0.000147	0.0324	CrCbGaD
Naproxen—Ibuprofen—PTGS2—pancreatic cancer	0.000145	0.0319	CrCbGaD
Naproxen—Asthenia—Gemcitabine—pancreatic cancer	7.15e-05	0.000347	CcSEcCtD
Naproxen—Haematuria—Epirubicin—pancreatic cancer	7.13e-05	0.000346	CcSEcCtD
Naproxen—Confusional state—Docetaxel—pancreatic cancer	7.13e-05	0.000346	CcSEcCtD
Naproxen—Photosensitivity reaction—Doxorubicin—pancreatic cancer	7.08e-05	0.000344	CcSEcCtD
Naproxen—Hepatobiliary disease—Epirubicin—pancreatic cancer	7.07e-05	0.000343	CcSEcCtD
Naproxen—Anaphylactic shock—Docetaxel—pancreatic cancer	7.07e-05	0.000343	CcSEcCtD
Naproxen—Oedema—Docetaxel—pancreatic cancer	7.07e-05	0.000343	CcSEcCtD
Naproxen—Epistaxis—Epirubicin—pancreatic cancer	7.05e-05	0.000342	CcSEcCtD
Naproxen—Pruritus—Gemcitabine—pancreatic cancer	7.05e-05	0.000342	CcSEcCtD
Naproxen—Infection—Docetaxel—pancreatic cancer	7.03e-05	0.000341	CcSEcCtD
Naproxen—Weight decreased—Doxorubicin—pancreatic cancer	7.02e-05	0.000341	CcSEcCtD
Naproxen—Sinusitis—Epirubicin—pancreatic cancer	7.02e-05	0.00034	CcSEcCtD
Naproxen—Hyperglycaemia—Doxorubicin—pancreatic cancer	7e-05	0.00034	CcSEcCtD
Naproxen—Diarrhoea—Irinotecan—pancreatic cancer	7e-05	0.000339	CcSEcCtD
Naproxen—Agranulocytosis—Epirubicin—pancreatic cancer	6.98e-05	0.000338	CcSEcCtD
Naproxen—Pneumonia—Doxorubicin—pancreatic cancer	6.96e-05	0.000338	CcSEcCtD
Naproxen—Shock—Docetaxel—pancreatic cancer	6.96e-05	0.000337	CcSEcCtD
Naproxen—Nervous system disorder—Docetaxel—pancreatic cancer	6.94e-05	0.000336	CcSEcCtD
Naproxen—Pruritus—Fluorouracil—pancreatic cancer	6.93e-05	0.000336	CcSEcCtD
Naproxen—Thrombocytopenia—Docetaxel—pancreatic cancer	6.92e-05	0.000336	CcSEcCtD
Naproxen—Drowsiness—Doxorubicin—pancreatic cancer	6.92e-05	0.000336	CcSEcCtD
Naproxen—Tachycardia—Docetaxel—pancreatic cancer	6.9e-05	0.000335	CcSEcCtD
Naproxen—Skin disorder—Docetaxel—pancreatic cancer	6.87e-05	0.000333	CcSEcCtD
Naproxen—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	6.86e-05	0.000333	CcSEcCtD
Naproxen—Diarrhoea—Gemcitabine—pancreatic cancer	6.82e-05	0.000331	CcSEcCtD
Naproxen—Renal failure—Doxorubicin—pancreatic cancer	6.8e-05	0.00033	CcSEcCtD
Naproxen—Neuropathy peripheral—Doxorubicin—pancreatic cancer	6.78e-05	0.000329	CcSEcCtD
Naproxen—Dizziness—Irinotecan—pancreatic cancer	6.77e-05	0.000328	CcSEcCtD
Naproxen—Haemoglobin—Epirubicin—pancreatic cancer	6.75e-05	0.000327	CcSEcCtD
Naproxen—Stomatitis—Doxorubicin—pancreatic cancer	6.75e-05	0.000327	CcSEcCtD
Naproxen—Jaundice—Doxorubicin—pancreatic cancer	6.75e-05	0.000327	CcSEcCtD
Naproxen—Anorexia—Docetaxel—pancreatic cancer	6.74e-05	0.000327	CcSEcCtD
Naproxen—Rhinitis—Epirubicin—pancreatic cancer	6.73e-05	0.000326	CcSEcCtD
Naproxen—Urinary tract infection—Doxorubicin—pancreatic cancer	6.73e-05	0.000326	CcSEcCtD
Naproxen—Conjunctivitis—Doxorubicin—pancreatic cancer	6.73e-05	0.000326	CcSEcCtD
Naproxen—Haemorrhage—Epirubicin—pancreatic cancer	6.71e-05	0.000326	CcSEcCtD
Naproxen—Hepatitis—Epirubicin—pancreatic cancer	6.71e-05	0.000326	CcSEcCtD
Naproxen—Diarrhoea—Fluorouracil—pancreatic cancer	6.7e-05	0.000325	CcSEcCtD
Naproxen—Pharyngitis—Epirubicin—pancreatic cancer	6.66e-05	0.000323	CcSEcCtD
Naproxen—Sweating—Doxorubicin—pancreatic cancer	6.63e-05	0.000322	CcSEcCtD
Naproxen—Urinary tract disorder—Epirubicin—pancreatic cancer	6.63e-05	0.000322	CcSEcCtD
Naproxen—Oedema peripheral—Epirubicin—pancreatic cancer	6.61e-05	0.000321	CcSEcCtD
Naproxen—Hypotension—Docetaxel—pancreatic cancer	6.61e-05	0.00032	CcSEcCtD
Naproxen—Haematuria—Doxorubicin—pancreatic cancer	6.6e-05	0.00032	CcSEcCtD
Naproxen—Connective tissue disorder—Epirubicin—pancreatic cancer	6.6e-05	0.00032	CcSEcCtD
Naproxen—Urethral disorder—Epirubicin—pancreatic cancer	6.58e-05	0.000319	CcSEcCtD
Naproxen—Hepatobiliary disease—Doxorubicin—pancreatic cancer	6.54e-05	0.000317	CcSEcCtD
Naproxen—Epistaxis—Doxorubicin—pancreatic cancer	6.53e-05	0.000317	CcSEcCtD
Naproxen—Vomiting—Irinotecan—pancreatic cancer	6.5e-05	0.000315	CcSEcCtD
Naproxen—Sinusitis—Doxorubicin—pancreatic cancer	6.49e-05	0.000315	CcSEcCtD
Naproxen—Dizziness—Fluorouracil—pancreatic cancer	6.48e-05	0.000314	CcSEcCtD
Naproxen—Visual impairment—Epirubicin—pancreatic cancer	6.47e-05	0.000314	CcSEcCtD
Naproxen—Agranulocytosis—Doxorubicin—pancreatic cancer	6.46e-05	0.000313	CcSEcCtD
Naproxen—Rash—Irinotecan—pancreatic cancer	6.45e-05	0.000313	CcSEcCtD
Naproxen—Dermatitis—Irinotecan—pancreatic cancer	6.44e-05	0.000313	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	6.44e-05	0.000312	CcSEcCtD
Naproxen—Headache—Irinotecan—pancreatic cancer	6.41e-05	0.000311	CcSEcCtD
Naproxen—Insomnia—Docetaxel—pancreatic cancer	6.4e-05	0.00031	CcSEcCtD
Naproxen—Paraesthesia—Docetaxel—pancreatic cancer	6.35e-05	0.000308	CcSEcCtD
Naproxen—Erythema multiforme—Epirubicin—pancreatic cancer	6.35e-05	0.000308	CcSEcCtD
Naproxen—Vomiting—Gemcitabine—pancreatic cancer	6.34e-05	0.000307	CcSEcCtD
Naproxen—Dyspnoea—Docetaxel—pancreatic cancer	6.31e-05	0.000306	CcSEcCtD
Naproxen—Somnolence—Docetaxel—pancreatic cancer	6.29e-05	0.000305	CcSEcCtD
Naproxen—Rash—Gemcitabine—pancreatic cancer	6.28e-05	0.000305	CcSEcCtD
Naproxen—Dermatitis—Gemcitabine—pancreatic cancer	6.28e-05	0.000304	CcSEcCtD
Naproxen—Eye disorder—Epirubicin—pancreatic cancer	6.27e-05	0.000304	CcSEcCtD
Naproxen—Tinnitus—Epirubicin—pancreatic cancer	6.26e-05	0.000304	CcSEcCtD
Naproxen—Haemoglobin—Doxorubicin—pancreatic cancer	6.24e-05	0.000303	CcSEcCtD
Naproxen—Headache—Gemcitabine—pancreatic cancer	6.24e-05	0.000303	CcSEcCtD
Naproxen—Cardiac disorder—Epirubicin—pancreatic cancer	6.23e-05	0.000302	CcSEcCtD
Naproxen—Vomiting—Fluorouracil—pancreatic cancer	6.23e-05	0.000302	CcSEcCtD
Naproxen—Rhinitis—Doxorubicin—pancreatic cancer	6.23e-05	0.000302	CcSEcCtD
Naproxen—Dyspepsia—Docetaxel—pancreatic cancer	6.23e-05	0.000302	CcSEcCtD
Naproxen—Haemorrhage—Doxorubicin—pancreatic cancer	6.21e-05	0.000301	CcSEcCtD
Naproxen—Hepatitis—Doxorubicin—pancreatic cancer	6.21e-05	0.000301	CcSEcCtD
Naproxen—Rash—Fluorouracil—pancreatic cancer	6.18e-05	0.0003	CcSEcCtD
Naproxen—Dermatitis—Fluorouracil—pancreatic cancer	6.17e-05	0.000299	CcSEcCtD
Naproxen—Pharyngitis—Doxorubicin—pancreatic cancer	6.17e-05	0.000299	CcSEcCtD
Naproxen—Decreased appetite—Docetaxel—pancreatic cancer	6.15e-05	0.000298	CcSEcCtD
Naproxen—Headache—Fluorouracil—pancreatic cancer	6.14e-05	0.000298	CcSEcCtD
Naproxen—Urinary tract disorder—Doxorubicin—pancreatic cancer	6.14e-05	0.000298	CcSEcCtD
Naproxen—Oedema peripheral—Doxorubicin—pancreatic cancer	6.12e-05	0.000297	CcSEcCtD
Naproxen—Gastrointestinal disorder—Docetaxel—pancreatic cancer	6.11e-05	0.000296	CcSEcCtD
Naproxen—Connective tissue disorder—Doxorubicin—pancreatic cancer	6.1e-05	0.000296	CcSEcCtD
Naproxen—Fatigue—Docetaxel—pancreatic cancer	6.1e-05	0.000296	CcSEcCtD
Naproxen—Angiopathy—Epirubicin—pancreatic cancer	6.09e-05	0.000295	CcSEcCtD
Naproxen—Urethral disorder—Doxorubicin—pancreatic cancer	6.09e-05	0.000295	CcSEcCtD
Naproxen—Nausea—Irinotecan—pancreatic cancer	6.08e-05	0.000295	CcSEcCtD
Naproxen—Immune system disorder—Epirubicin—pancreatic cancer	6.06e-05	0.000294	CcSEcCtD
Naproxen—Mediastinal disorder—Epirubicin—pancreatic cancer	6.05e-05	0.000293	CcSEcCtD
Naproxen—Pain—Docetaxel—pancreatic cancer	6.05e-05	0.000293	CcSEcCtD
Naproxen—Constipation—Docetaxel—pancreatic cancer	6.05e-05	0.000293	CcSEcCtD
Naproxen—Chills—Epirubicin—pancreatic cancer	6.02e-05	0.000292	CcSEcCtD
Naproxen—Arrhythmia—Epirubicin—pancreatic cancer	6e-05	0.000291	CcSEcCtD
Naproxen—Visual impairment—Doxorubicin—pancreatic cancer	5.99e-05	0.00029	CcSEcCtD
Naproxen—Alopecia—Epirubicin—pancreatic cancer	5.93e-05	0.000288	CcSEcCtD
Naproxen—Nausea—Gemcitabine—pancreatic cancer	5.92e-05	0.000287	CcSEcCtD
Naproxen—Mental disorder—Epirubicin—pancreatic cancer	5.88e-05	0.000285	CcSEcCtD
Naproxen—Erythema multiforme—Doxorubicin—pancreatic cancer	5.87e-05	0.000285	CcSEcCtD
Naproxen—Malnutrition—Epirubicin—pancreatic cancer	5.84e-05	0.000283	CcSEcCtD
Naproxen—Erythema—Epirubicin—pancreatic cancer	5.84e-05	0.000283	CcSEcCtD
Naproxen—Feeling abnormal—Docetaxel—pancreatic cancer	5.83e-05	0.000283	CcSEcCtD
Naproxen—Nausea—Fluorouracil—pancreatic cancer	5.82e-05	0.000282	CcSEcCtD
Naproxen—Eye disorder—Doxorubicin—pancreatic cancer	5.81e-05	0.000282	CcSEcCtD
Naproxen—Tinnitus—Doxorubicin—pancreatic cancer	5.79e-05	0.000281	CcSEcCtD
Naproxen—Gastrointestinal pain—Docetaxel—pancreatic cancer	5.78e-05	0.00028	CcSEcCtD
Naproxen—Cardiac disorder—Doxorubicin—pancreatic cancer	5.77e-05	0.00028	CcSEcCtD
Naproxen—Flatulence—Epirubicin—pancreatic cancer	5.76e-05	0.000279	CcSEcCtD
Naproxen—Tension—Epirubicin—pancreatic cancer	5.74e-05	0.000278	CcSEcCtD
Naproxen—Nervousness—Epirubicin—pancreatic cancer	5.68e-05	0.000275	CcSEcCtD
Naproxen—Angiopathy—Doxorubicin—pancreatic cancer	5.64e-05	0.000273	CcSEcCtD
Naproxen—Muscle spasms—Epirubicin—pancreatic cancer	5.62e-05	0.000273	CcSEcCtD
Naproxen—Immune system disorder—Doxorubicin—pancreatic cancer	5.61e-05	0.000272	CcSEcCtD
Naproxen—Mediastinal disorder—Doxorubicin—pancreatic cancer	5.6e-05	0.000272	CcSEcCtD
Naproxen—Abdominal pain—Docetaxel—pancreatic cancer	5.59e-05	0.000271	CcSEcCtD
Naproxen—Body temperature increased—Docetaxel—pancreatic cancer	5.59e-05	0.000271	CcSEcCtD
Naproxen—Chills—Doxorubicin—pancreatic cancer	5.57e-05	0.00027	CcSEcCtD
Naproxen—Arrhythmia—Doxorubicin—pancreatic cancer	5.55e-05	0.000269	CcSEcCtD
Naproxen—Vision blurred—Epirubicin—pancreatic cancer	5.51e-05	0.000267	CcSEcCtD
Naproxen—Alopecia—Doxorubicin—pancreatic cancer	5.49e-05	0.000266	CcSEcCtD
Naproxen—Mental disorder—Doxorubicin—pancreatic cancer	5.44e-05	0.000264	CcSEcCtD
Naproxen—Ill-defined disorder—Epirubicin—pancreatic cancer	5.42e-05	0.000263	CcSEcCtD
Naproxen—Malnutrition—Doxorubicin—pancreatic cancer	5.41e-05	0.000262	CcSEcCtD
Naproxen—Erythema—Doxorubicin—pancreatic cancer	5.41e-05	0.000262	CcSEcCtD
Naproxen—Anaemia—Epirubicin—pancreatic cancer	5.4e-05	0.000262	CcSEcCtD
Naproxen—Flatulence—Doxorubicin—pancreatic cancer	5.33e-05	0.000258	CcSEcCtD
Naproxen—Tension—Doxorubicin—pancreatic cancer	5.31e-05	0.000257	CcSEcCtD
Naproxen—Malaise—Epirubicin—pancreatic cancer	5.27e-05	0.000256	CcSEcCtD
Naproxen—Nervousness—Doxorubicin—pancreatic cancer	5.25e-05	0.000255	CcSEcCtD
Naproxen—Vertigo—Epirubicin—pancreatic cancer	5.25e-05	0.000255	CcSEcCtD
Naproxen—Syncope—Epirubicin—pancreatic cancer	5.24e-05	0.000254	CcSEcCtD
Naproxen—Leukopenia—Epirubicin—pancreatic cancer	5.23e-05	0.000254	CcSEcCtD
Naproxen—Hypersensitivity—Docetaxel—pancreatic cancer	5.21e-05	0.000253	CcSEcCtD
Naproxen—Muscle spasms—Doxorubicin—pancreatic cancer	5.2e-05	0.000252	CcSEcCtD
Naproxen—Palpitations—Epirubicin—pancreatic cancer	5.17e-05	0.00025	CcSEcCtD
Naproxen—Loss of consciousness—Epirubicin—pancreatic cancer	5.14e-05	0.000249	CcSEcCtD
Naproxen—Cough—Epirubicin—pancreatic cancer	5.1e-05	0.000247	CcSEcCtD
Naproxen—Vision blurred—Doxorubicin—pancreatic cancer	5.1e-05	0.000247	CcSEcCtD
Naproxen—Asthenia—Docetaxel—pancreatic cancer	5.07e-05	0.000246	CcSEcCtD
Naproxen—Convulsion—Epirubicin—pancreatic cancer	5.06e-05	0.000246	CcSEcCtD
Naproxen—Hypertension—Epirubicin—pancreatic cancer	5.05e-05	0.000245	CcSEcCtD
Naproxen—Ill-defined disorder—Doxorubicin—pancreatic cancer	5.02e-05	0.000243	CcSEcCtD
Naproxen—Pruritus—Docetaxel—pancreatic cancer	5e-05	0.000243	CcSEcCtD
Naproxen—Anaemia—Doxorubicin—pancreatic cancer	5e-05	0.000242	CcSEcCtD
Naproxen—Arthralgia—Epirubicin—pancreatic cancer	4.98e-05	0.000241	CcSEcCtD
Naproxen—Myalgia—Epirubicin—pancreatic cancer	4.98e-05	0.000241	CcSEcCtD
Naproxen—Chest pain—Epirubicin—pancreatic cancer	4.98e-05	0.000241	CcSEcCtD
Naproxen—Anxiety—Epirubicin—pancreatic cancer	4.96e-05	0.00024	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	4.94e-05	0.00024	CcSEcCtD
Naproxen—Discomfort—Epirubicin—pancreatic cancer	4.92e-05	0.000238	CcSEcCtD
Naproxen—Malaise—Doxorubicin—pancreatic cancer	4.88e-05	0.000237	CcSEcCtD
Naproxen—Dry mouth—Epirubicin—pancreatic cancer	4.87e-05	0.000236	CcSEcCtD
Naproxen—Vertigo—Doxorubicin—pancreatic cancer	4.86e-05	0.000236	CcSEcCtD
Naproxen—Syncope—Doxorubicin—pancreatic cancer	4.85e-05	0.000235	CcSEcCtD
Naproxen—Leukopenia—Doxorubicin—pancreatic cancer	4.84e-05	0.000235	CcSEcCtD
Naproxen—Diarrhoea—Docetaxel—pancreatic cancer	4.84e-05	0.000235	CcSEcCtD
Naproxen—Confusional state—Epirubicin—pancreatic cancer	4.81e-05	0.000233	CcSEcCtD
Naproxen—Palpitations—Doxorubicin—pancreatic cancer	4.78e-05	0.000232	CcSEcCtD
Naproxen—Oedema—Epirubicin—pancreatic cancer	4.77e-05	0.000231	CcSEcCtD
Naproxen—Anaphylactic shock—Epirubicin—pancreatic cancer	4.77e-05	0.000231	CcSEcCtD
Naproxen—Loss of consciousness—Doxorubicin—pancreatic cancer	4.75e-05	0.000231	CcSEcCtD
Naproxen—Infection—Epirubicin—pancreatic cancer	4.74e-05	0.00023	CcSEcCtD
Naproxen—Cough—Doxorubicin—pancreatic cancer	4.72e-05	0.000229	CcSEcCtD
Naproxen—Shock—Epirubicin—pancreatic cancer	4.69e-05	0.000228	CcSEcCtD
Naproxen—Convulsion—Doxorubicin—pancreatic cancer	4.69e-05	0.000227	CcSEcCtD
Naproxen—Nervous system disorder—Epirubicin—pancreatic cancer	4.68e-05	0.000227	CcSEcCtD
Naproxen—Dizziness—Docetaxel—pancreatic cancer	4.68e-05	0.000227	CcSEcCtD
Naproxen—Thrombocytopenia—Epirubicin—pancreatic cancer	4.67e-05	0.000226	CcSEcCtD
Naproxen—Hypertension—Doxorubicin—pancreatic cancer	4.67e-05	0.000226	CcSEcCtD
Naproxen—Tachycardia—Epirubicin—pancreatic cancer	4.66e-05	0.000226	CcSEcCtD
Naproxen—Skin disorder—Epirubicin—pancreatic cancer	4.63e-05	0.000225	CcSEcCtD
Naproxen—Hyperhidrosis—Epirubicin—pancreatic cancer	4.61e-05	0.000224	CcSEcCtD
Naproxen—Arthralgia—Doxorubicin—pancreatic cancer	4.6e-05	0.000223	CcSEcCtD
Naproxen—Myalgia—Doxorubicin—pancreatic cancer	4.6e-05	0.000223	CcSEcCtD
Naproxen—Chest pain—Doxorubicin—pancreatic cancer	4.6e-05	0.000223	CcSEcCtD
Naproxen—Anxiety—Doxorubicin—pancreatic cancer	4.59e-05	0.000223	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	4.57e-05	0.000222	CcSEcCtD
Naproxen—Discomfort—Doxorubicin—pancreatic cancer	4.55e-05	0.000221	CcSEcCtD
Naproxen—Anorexia—Epirubicin—pancreatic cancer	4.55e-05	0.000221	CcSEcCtD
Naproxen—Dry mouth—Doxorubicin—pancreatic cancer	4.5e-05	0.000218	CcSEcCtD
Naproxen—Vomiting—Docetaxel—pancreatic cancer	4.5e-05	0.000218	CcSEcCtD
Naproxen—Rash—Docetaxel—pancreatic cancer	4.46e-05	0.000216	CcSEcCtD
Naproxen—Hypotension—Epirubicin—pancreatic cancer	4.46e-05	0.000216	CcSEcCtD
Naproxen—Dermatitis—Docetaxel—pancreatic cancer	4.45e-05	0.000216	CcSEcCtD
Naproxen—Confusional state—Doxorubicin—pancreatic cancer	4.45e-05	0.000216	CcSEcCtD
Naproxen—Headache—Docetaxel—pancreatic cancer	4.43e-05	0.000215	CcSEcCtD
Naproxen—Oedema—Doxorubicin—pancreatic cancer	4.41e-05	0.000214	CcSEcCtD
Naproxen—Anaphylactic shock—Doxorubicin—pancreatic cancer	4.41e-05	0.000214	CcSEcCtD
Naproxen—Infection—Doxorubicin—pancreatic cancer	4.38e-05	0.000213	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	4.35e-05	0.000211	CcSEcCtD
Naproxen—Shock—Doxorubicin—pancreatic cancer	4.34e-05	0.000211	CcSEcCtD
Naproxen—Nervous system disorder—Doxorubicin—pancreatic cancer	4.33e-05	0.00021	CcSEcCtD
Naproxen—Thrombocytopenia—Doxorubicin—pancreatic cancer	4.32e-05	0.00021	CcSEcCtD
Naproxen—Insomnia—Epirubicin—pancreatic cancer	4.31e-05	0.000209	CcSEcCtD
Naproxen—Tachycardia—Doxorubicin—pancreatic cancer	4.31e-05	0.000209	CcSEcCtD
Naproxen—Skin disorder—Doxorubicin—pancreatic cancer	4.29e-05	0.000208	CcSEcCtD
Naproxen—Paraesthesia—Epirubicin—pancreatic cancer	4.28e-05	0.000208	CcSEcCtD
Naproxen—Hyperhidrosis—Doxorubicin—pancreatic cancer	4.27e-05	0.000207	CcSEcCtD
Naproxen—Dyspnoea—Epirubicin—pancreatic cancer	4.25e-05	0.000206	CcSEcCtD
Naproxen—Somnolence—Epirubicin—pancreatic cancer	4.24e-05	0.000206	CcSEcCtD
Naproxen—Anorexia—Doxorubicin—pancreatic cancer	4.21e-05	0.000204	CcSEcCtD
Naproxen—Nausea—Docetaxel—pancreatic cancer	4.2e-05	0.000204	CcSEcCtD
Naproxen—Dyspepsia—Epirubicin—pancreatic cancer	4.2e-05	0.000204	CcSEcCtD
Naproxen—Decreased appetite—Epirubicin—pancreatic cancer	4.15e-05	0.000201	CcSEcCtD
Naproxen—Hypotension—Doxorubicin—pancreatic cancer	4.12e-05	0.0002	CcSEcCtD
Naproxen—Gastrointestinal disorder—Epirubicin—pancreatic cancer	4.12e-05	0.0002	CcSEcCtD
Naproxen—Fatigue—Epirubicin—pancreatic cancer	4.11e-05	0.000199	CcSEcCtD
Naproxen—Constipation—Epirubicin—pancreatic cancer	4.08e-05	0.000198	CcSEcCtD
Naproxen—Pain—Epirubicin—pancreatic cancer	4.08e-05	0.000198	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	4.02e-05	0.000195	CcSEcCtD
Naproxen—Insomnia—Doxorubicin—pancreatic cancer	3.99e-05	0.000194	CcSEcCtD
Naproxen—Paraesthesia—Doxorubicin—pancreatic cancer	3.96e-05	0.000192	CcSEcCtD
Naproxen—Dyspnoea—Doxorubicin—pancreatic cancer	3.93e-05	0.000191	CcSEcCtD
Naproxen—Feeling abnormal—Epirubicin—pancreatic cancer	3.93e-05	0.000191	CcSEcCtD
Naproxen—Somnolence—Doxorubicin—pancreatic cancer	3.92e-05	0.00019	CcSEcCtD
Naproxen—Gastrointestinal pain—Epirubicin—pancreatic cancer	3.9e-05	0.000189	CcSEcCtD
Naproxen—Dyspepsia—Doxorubicin—pancreatic cancer	3.89e-05	0.000188	CcSEcCtD
Naproxen—Decreased appetite—Doxorubicin—pancreatic cancer	3.84e-05	0.000186	CcSEcCtD
Naproxen—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	3.81e-05	0.000185	CcSEcCtD
Naproxen—Fatigue—Doxorubicin—pancreatic cancer	3.81e-05	0.000185	CcSEcCtD
Naproxen—Urticaria—Epirubicin—pancreatic cancer	3.79e-05	0.000184	CcSEcCtD
Naproxen—Pain—Doxorubicin—pancreatic cancer	3.77e-05	0.000183	CcSEcCtD
Naproxen—Constipation—Doxorubicin—pancreatic cancer	3.77e-05	0.000183	CcSEcCtD
Naproxen—Body temperature increased—Epirubicin—pancreatic cancer	3.77e-05	0.000183	CcSEcCtD
Naproxen—Abdominal pain—Epirubicin—pancreatic cancer	3.77e-05	0.000183	CcSEcCtD
Naproxen—Feeling abnormal—Doxorubicin—pancreatic cancer	3.64e-05	0.000176	CcSEcCtD
Naproxen—Gastrointestinal pain—Doxorubicin—pancreatic cancer	3.61e-05	0.000175	CcSEcCtD
Naproxen—Hypersensitivity—Epirubicin—pancreatic cancer	3.51e-05	0.00017	CcSEcCtD
Naproxen—Urticaria—Doxorubicin—pancreatic cancer	3.51e-05	0.00017	CcSEcCtD
Naproxen—Body temperature increased—Doxorubicin—pancreatic cancer	3.49e-05	0.000169	CcSEcCtD
Naproxen—Abdominal pain—Doxorubicin—pancreatic cancer	3.49e-05	0.000169	CcSEcCtD
Naproxen—Asthenia—Epirubicin—pancreatic cancer	3.42e-05	0.000166	CcSEcCtD
Naproxen—Pruritus—Epirubicin—pancreatic cancer	3.37e-05	0.000164	CcSEcCtD
Naproxen—Diarrhoea—Epirubicin—pancreatic cancer	3.26e-05	0.000158	CcSEcCtD
Naproxen—Hypersensitivity—Doxorubicin—pancreatic cancer	3.25e-05	0.000158	CcSEcCtD
Naproxen—Asthenia—Doxorubicin—pancreatic cancer	3.17e-05	0.000154	CcSEcCtD
Naproxen—Dizziness—Epirubicin—pancreatic cancer	3.15e-05	0.000153	CcSEcCtD
Naproxen—Pruritus—Doxorubicin—pancreatic cancer	3.12e-05	0.000151	CcSEcCtD
Naproxen—Vomiting—Epirubicin—pancreatic cancer	3.03e-05	0.000147	CcSEcCtD
Naproxen—Diarrhoea—Doxorubicin—pancreatic cancer	3.02e-05	0.000146	CcSEcCtD
Naproxen—Rash—Epirubicin—pancreatic cancer	3.01e-05	0.000146	CcSEcCtD
Naproxen—Dermatitis—Epirubicin—pancreatic cancer	3e-05	0.000146	CcSEcCtD
Naproxen—Headache—Epirubicin—pancreatic cancer	2.99e-05	0.000145	CcSEcCtD
Naproxen—Dizziness—Doxorubicin—pancreatic cancer	2.92e-05	0.000142	CcSEcCtD
Naproxen—Nausea—Epirubicin—pancreatic cancer	2.83e-05	0.000137	CcSEcCtD
Naproxen—Vomiting—Doxorubicin—pancreatic cancer	2.81e-05	0.000136	CcSEcCtD
Naproxen—Rash—Doxorubicin—pancreatic cancer	2.78e-05	0.000135	CcSEcCtD
Naproxen—Dermatitis—Doxorubicin—pancreatic cancer	2.78e-05	0.000135	CcSEcCtD
Naproxen—Headache—Doxorubicin—pancreatic cancer	2.77e-05	0.000134	CcSEcCtD
Naproxen—Nausea—Doxorubicin—pancreatic cancer	2.62e-05	0.000127	CcSEcCtD
Naproxen—PTGS2—Metabolism—DPYD—pancreatic cancer	8.25e-06	0.000533	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—SRC—pancreatic cancer	8.2e-06	0.00053	CbGpPWpGaD
Naproxen—AKR1C3—Disease—CTNNB1—pancreatic cancer	8.1e-06	0.000523	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—VEGFA—pancreatic cancer	7.99e-06	0.000516	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PTEN—pancreatic cancer	7.89e-06	0.00051	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ARG2—pancreatic cancer	7.88e-06	0.000509	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—SLC2A2—pancreatic cancer	7.83e-06	0.000506	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—TYMS—pancreatic cancer	7.78e-06	0.000503	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PRSS1—pancreatic cancer	7.77e-06	0.000502	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	7.75e-06	0.0005	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PLAU—pancreatic cancer	7.74e-06	0.0005	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PIK3CB—pancreatic cancer	7.65e-06	0.000494	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CD44—pancreatic cancer	7.63e-06	0.000493	CbGpPWpGaD
Naproxen—PTGS2—Disease—JAG1—pancreatic cancer	7.62e-06	0.000492	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PTGS2—pancreatic cancer	7.58e-06	0.00049	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	7.48e-06	0.000483	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	7.48e-06	0.000483	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	7.41e-06	0.000478	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PIK3CD—pancreatic cancer	7.34e-06	0.000474	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—TGFB1—pancreatic cancer	7.33e-06	0.000473	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GCG—pancreatic cancer	7.32e-06	0.000473	CbGpPWpGaD
Naproxen—AKR1C3—Disease—SRC—pancreatic cancer	7.32e-06	0.000473	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—APOE—pancreatic cancer	7.27e-06	0.000469	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—TYMS—pancreatic cancer	7.26e-06	0.000469	CbGpPWpGaD
Naproxen—PTGS2—Disease—CD44—pancreatic cancer	7.24e-06	0.000467	CbGpPWpGaD
Naproxen—PTGS2—Disease—HSPA1A—pancreatic cancer	7.18e-06	0.000464	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	7.08e-06	0.000457	CbGpPWpGaD
Naproxen—AKR1C3—Disease—STAT3—pancreatic cancer	7.06e-06	0.000456	CbGpPWpGaD
Naproxen—AKR1C3—Disease—NRAS—pancreatic cancer	7.04e-06	0.000455	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	6.98e-06	0.000451	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	6.94e-06	0.000448	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—TYMP—pancreatic cancer	6.89e-06	0.000445	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PIK3CG—pancreatic cancer	6.88e-06	0.000445	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—STK11—pancreatic cancer	6.88e-06	0.000445	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GLP1R—pancreatic cancer	6.82e-06	0.000441	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	6.81e-06	0.00044	CbGpPWpGaD
Naproxen—ALB—Hemostasis—EGF—pancreatic cancer	6.8e-06	0.000439	CbGpPWpGaD
Naproxen—ALB—Metabolism—GLP1R—pancreatic cancer	6.78e-06	0.000438	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ARG2—pancreatic cancer	6.73e-06	0.000435	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—DPYD—pancreatic cancer	6.71e-06	0.000433	CbGpPWpGaD
Naproxen—ALB—Metabolism—DPYD—pancreatic cancer	6.67e-06	0.000431	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PTEN—pancreatic cancer	6.61e-06	0.000427	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PIK3CG—pancreatic cancer	6.56e-06	0.000424	CbGpPWpGaD
Naproxen—AKR1C3—Disease—MYC—pancreatic cancer	6.56e-06	0.000424	CbGpPWpGaD
Naproxen—AKR1C3—Disease—TGFB1—pancreatic cancer	6.54e-06	0.000423	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	6.46e-06	0.000417	CbGpPWpGaD
Naproxen—AKR1C3—Disease—EGFR—pancreatic cancer	6.42e-06	0.000414	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PIK3CB—pancreatic cancer	6.4e-06	0.000413	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—SLC2A2—pancreatic cancer	6.37e-06	0.000411	CbGpPWpGaD
Naproxen—ALB—Metabolism—SLC2A2—pancreatic cancer	6.33e-06	0.000409	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PPARG—pancreatic cancer	6.33e-06	0.000409	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—APOE—pancreatic cancer	6.33e-06	0.000409	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	6.3e-06	0.000407	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	6.27e-06	0.000405	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—PIK3CA—pancreatic cancer	6.24e-06	0.000403	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CXCL8—pancreatic cancer	6.15e-06	0.000397	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	6.08e-06	0.000393	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CD44—pancreatic cancer	6.06e-06	0.000391	CbGpPWpGaD
Naproxen—AKR1C3—Disease—KRAS—pancreatic cancer	6.06e-06	0.000391	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PIK3CD—pancreatic cancer	6.05e-06	0.000391	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	6.05e-06	0.000391	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	5.99e-06	0.000387	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	5.93e-06	0.000383	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—TYMS—pancreatic cancer	5.92e-06	0.000382	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—APOE—pancreatic cancer	5.91e-06	0.000381	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—TYMP—pancreatic cancer	5.89e-06	0.00038	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CASP3—pancreatic cancer	5.88e-06	0.00038	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GCG—pancreatic cancer	5.81e-06	0.000375	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PIK3CD—pancreatic cancer	5.77e-06	0.000372	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CCND1—pancreatic cancer	5.73e-06	0.00037	CbGpPWpGaD
Naproxen—PTGS2—Disease—SMAD4—pancreatic cancer	5.71e-06	0.000369	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CG—pancreatic cancer	5.71e-06	0.000369	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	5.68e-06	0.000367	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CTNNB1—pancreatic cancer	5.67e-06	0.000366	CbGpPWpGaD
Naproxen—PTGS2—Disease—HES1—pancreatic cancer	5.58e-06	0.00036	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PIK3CA—pancreatic cancer	5.57e-06	0.00036	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MMP9—pancreatic cancer	5.56e-06	0.000359	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GLP1R—pancreatic cancer	5.55e-06	0.000359	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	5.54e-06	0.000358	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PTEN—pancreatic cancer	5.53e-06	0.000357	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PPARG—pancreatic cancer	5.51e-06	0.000356	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	5.51e-06	0.000356	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—STK11—pancreatic cancer	5.46e-06	0.000353	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—DPYD—pancreatic cancer	5.46e-06	0.000353	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CG—pancreatic cancer	5.33e-06	0.000344	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PIK3CB—pancreatic cancer	5.27e-06	0.000341	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—SLC2A2—pancreatic cancer	5.18e-06	0.000335	CbGpPWpGaD
Naproxen—AKR1C3—Disease—HRAS—pancreatic cancer	5.15e-06	0.000333	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PPARG—pancreatic cancer	5.14e-06	0.000332	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	5.13e-06	0.000331	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	5.13e-06	0.000331	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SRC—pancreatic cancer	5.13e-06	0.000331	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—AKT1—pancreatic cancer	5.1e-06	0.000329	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PIK3CB—pancreatic cancer	5.03e-06	0.000325	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CD—pancreatic cancer	5.02e-06	0.000324	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—VEGFA—pancreatic cancer	4.99e-06	0.000322	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTGS2—pancreatic cancer	4.98e-06	0.000322	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	4.95e-06	0.00032	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—STAT3—pancreatic cancer	4.94e-06	0.000319	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CD44—pancreatic cancer	4.93e-06	0.000319	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—NRAS—pancreatic cancer	4.93e-06	0.000318	CbGpPWpGaD
Naproxen—ALB—Metabolism—CD44—pancreatic cancer	4.9e-06	0.000317	CbGpPWpGaD
Naproxen—PTGS2—Disease—TERT—pancreatic cancer	4.89e-06	0.000316	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	4.86e-06	0.000314	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	4.83e-06	0.000312	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—APOE—pancreatic cancer	4.81e-06	0.000311	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	4.8e-06	0.00031	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	4.78e-06	0.000309	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	4.76e-06	0.000307	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GLP1R—pancreatic cancer	4.74e-06	0.000306	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GCG—pancreatic cancer	4.73e-06	0.000305	CbGpPWpGaD
Naproxen—ALB—Metabolism—GCG—pancreatic cancer	4.7e-06	0.000304	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—TYMS—pancreatic cancer	4.7e-06	0.000304	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CD—pancreatic cancer	4.69e-06	0.000303	CbGpPWpGaD
Naproxen—PTGS2—Disease—HIF1A—pancreatic cancer	4.68e-06	0.000302	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—DPYD—pancreatic cancer	4.67e-06	0.000301	CbGpPWpGaD
Naproxen—PTGS2—Disease—TSC2—pancreatic cancer	4.66e-06	0.000301	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PIK3CA—pancreatic cancer	4.66e-06	0.000301	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MYC—pancreatic cancer	4.59e-06	0.000297	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TGFB1—pancreatic cancer	4.58e-06	0.000296	CbGpPWpGaD
Naproxen—PTGS2—Disease—APOE—pancreatic cancer	4.56e-06	0.000295	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.56e-06	0.000294	CbGpPWpGaD
Naproxen—AKR1C3—Disease—AKT1—pancreatic cancer	4.55e-06	0.000294	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	4.51e-06	0.000291	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—EGFR—pancreatic cancer	4.49e-06	0.00029	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—STK11—pancreatic cancer	4.45e-06	0.000287	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	4.43e-06	0.000286	CbGpPWpGaD
Naproxen—ALB—Metabolism—STK11—pancreatic cancer	4.42e-06	0.000285	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	4.38e-06	0.000283	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CB—pancreatic cancer	4.38e-06	0.000283	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CG—pancreatic cancer	4.35e-06	0.000281	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTEN—pancreatic cancer	4.34e-06	0.000281	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTGS2—pancreatic cancer	4.34e-06	0.00028	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—KRAS—pancreatic cancer	4.24e-06	0.000274	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	4.23e-06	0.000273	CbGpPWpGaD
Naproxen—ALB—Hemostasis—SRC—pancreatic cancer	4.23e-06	0.000273	CbGpPWpGaD
Naproxen—PTGS2—Disease—NOTCH1—pancreatic cancer	4.21e-06	0.000272	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PPARG—pancreatic cancer	4.19e-06	0.000271	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	4.17e-06	0.00027	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	4.15e-06	0.000268	CbGpPWpGaD
Naproxen—ALB—Hemostasis—VEGFA—pancreatic cancer	4.12e-06	0.000266	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CB—pancreatic cancer	4.08e-06	0.000264	CbGpPWpGaD
Naproxen—PTGS2—Disease—EGF—pancreatic cancer	4.07e-06	0.000263	CbGpPWpGaD
Naproxen—ALB—Hemostasis—NRAS—pancreatic cancer	4.07e-06	0.000263	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTGS2—pancreatic cancer	4.05e-06	0.000261	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CD44—pancreatic cancer	4.01e-06	0.000259	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	3.93e-06	0.000254	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PIK3CA—pancreatic cancer	3.9e-06	0.000252	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	3.89e-06	0.000252	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	3.85e-06	0.000249	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GCG—pancreatic cancer	3.85e-06	0.000249	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—TYMS—pancreatic cancer	3.82e-06	0.000247	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—APOE—pancreatic cancer	3.82e-06	0.000247	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CD—pancreatic cancer	3.82e-06	0.000247	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—AKT1—pancreatic cancer	3.81e-06	0.000246	CbGpPWpGaD
Naproxen—ALB—Metabolism—TYMS—pancreatic cancer	3.8e-06	0.000246	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTEN—pancreatic cancer	3.78e-06	0.000244	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TGFB1—pancreatic cancer	3.78e-06	0.000244	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TP53—pancreatic cancer	3.77e-06	0.000244	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CD—pancreatic cancer	3.62e-06	0.000234	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—STK11—pancreatic cancer	3.62e-06	0.000234	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.62e-06	0.000234	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—HRAS—pancreatic cancer	3.61e-06	0.000233	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTEN—pancreatic cancer	3.53e-06	0.000228	CbGpPWpGaD
Naproxen—ALB—Hemostasis—KRAS—pancreatic cancer	3.5e-06	0.000226	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CG—pancreatic cancer	3.45e-06	0.000223	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CD44—pancreatic cancer	3.43e-06	0.000222	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	3.4e-06	0.000219	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	3.36e-06	0.000217	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CB—pancreatic cancer	3.33e-06	0.000215	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PPARG—pancreatic cancer	3.33e-06	0.000215	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	3.33e-06	0.000215	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTGS2—pancreatic cancer	3.3e-06	0.000213	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GCG—pancreatic cancer	3.29e-06	0.000212	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PIK3CA—pancreatic cancer	3.22e-06	0.000208	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—AKT1—pancreatic cancer	3.19e-06	0.000206	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CB—pancreatic cancer	3.16e-06	0.000204	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—TYMS—pancreatic cancer	3.11e-06	0.000201	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TP53—pancreatic cancer	3.11e-06	0.000201	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—APOE—pancreatic cancer	3.11e-06	0.000201	CbGpPWpGaD
Naproxen—ALB—Metabolism—APOE—pancreatic cancer	3.09e-06	0.0002	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—STK11—pancreatic cancer	3.09e-06	0.0002	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PIK3CA—pancreatic cancer	3.06e-06	0.000198	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CD—pancreatic cancer	3.03e-06	0.000196	CbGpPWpGaD
Naproxen—ALB—Hemostasis—HRAS—pancreatic cancer	2.97e-06	0.000192	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.94e-06	0.00019	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.93e-06	0.000189	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.9e-06	0.000187	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTEN—pancreatic cancer	2.88e-06	0.000186	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CG—pancreatic cancer	2.81e-06	0.000181	CbGpPWpGaD
Naproxen—PTGS2—Disease—CTNNB1—pancreatic cancer	2.8e-06	0.000181	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CG—pancreatic cancer	2.79e-06	0.00018	CbGpPWpGaD
Naproxen—PTGS2—Disease—PTEN—pancreatic cancer	2.73e-06	0.000176	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PPARG—pancreatic cancer	2.71e-06	0.000175	CbGpPWpGaD
Naproxen—ALB—Metabolism—PPARG—pancreatic cancer	2.69e-06	0.000174	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CA—pancreatic cancer	2.67e-06	0.000172	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—TYMS—pancreatic cancer	2.66e-06	0.000172	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CB—pancreatic cancer	2.64e-06	0.000171	CbGpPWpGaD
Naproxen—ALB—Hemostasis—AKT1—pancreatic cancer	2.63e-06	0.00017	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—APOE—pancreatic cancer	2.53e-06	0.000163	CbGpPWpGaD
Naproxen—PTGS2—Disease—SRC—pancreatic cancer	2.53e-06	0.000163	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—AKT1—pancreatic cancer	2.5e-06	0.000162	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CA—pancreatic cancer	2.49e-06	0.000161	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CD—pancreatic cancer	2.47e-06	0.000159	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CD—pancreatic cancer	2.45e-06	0.000158	CbGpPWpGaD
Naproxen—PTGS2—Disease—STAT3—pancreatic cancer	2.44e-06	0.000158	CbGpPWpGaD
Naproxen—PTGS2—Disease—NRAS—pancreatic cancer	2.43e-06	0.000157	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.4e-06	0.000155	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	2.28e-06	0.000148	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PTEN—pancreatic cancer	2.28e-06	0.000148	CbGpPWpGaD
Naproxen—PTGS2—Disease—MYC—pancreatic cancer	2.27e-06	0.000146	CbGpPWpGaD
Naproxen—PTGS2—Disease—TGFB1—pancreatic cancer	2.26e-06	0.000146	CbGpPWpGaD
Naproxen—PTGS2—Disease—EGFR—pancreatic cancer	2.22e-06	0.000143	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PPARG—pancreatic cancer	2.2e-06	0.000142	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—AKT1—pancreatic cancer	2.18e-06	0.000141	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—APOE—pancreatic cancer	2.16e-06	0.00014	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CB—pancreatic cancer	2.15e-06	0.000139	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CB—pancreatic cancer	2.14e-06	0.000138	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTGS2—pancreatic cancer	2.13e-06	0.000138	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTGS2—pancreatic cancer	2.12e-06	0.000137	CbGpPWpGaD
Naproxen—PTGS2—Disease—KRAS—pancreatic cancer	2.09e-06	0.000135	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.05e-06	0.000132	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—AKT1—pancreatic cancer	2.03e-06	0.000131	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CA—pancreatic cancer	2.03e-06	0.000131	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	2.01e-06	0.00013	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	1.95e-06	0.000126	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CA—pancreatic cancer	1.92e-06	0.000124	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PPARG—pancreatic cancer	1.88e-06	0.000122	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTEN—pancreatic cancer	1.86e-06	0.00012	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTEN—pancreatic cancer	1.85e-06	0.000119	CbGpPWpGaD
Naproxen—PTGS2—Disease—HRAS—pancreatic cancer	1.78e-06	0.000115	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	1.75e-06	0.000113	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTGS2—pancreatic cancer	1.73e-06	0.000112	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	1.72e-06	0.000111	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—AKT1—pancreatic cancer	1.66e-06	0.000107	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CA—pancreatic cancer	1.61e-06	0.000104	CbGpPWpGaD
Naproxen—PTGS2—Disease—AKT1—pancreatic cancer	1.57e-06	0.000102	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTEN—pancreatic cancer	1.51e-06	9.77e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	1.5e-06	9.66e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTGS2—pancreatic cancer	1.48e-06	9.57e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—AKT1—pancreatic cancer	1.32e-06	8.5e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CA—pancreatic cancer	1.31e-06	8.47e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CA—pancreatic cancer	1.3e-06	8.42e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTEN—pancreatic cancer	1.29e-06	8.35e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—AKT1—pancreatic cancer	1.07e-06	6.92e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	1.07e-06	6.89e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—AKT1—pancreatic cancer	1.06e-06	6.88e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	9.12e-07	5.89e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—AKT1—pancreatic cancer	8.72e-07	5.63e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—AKT1—pancreatic cancer	7.45e-07	4.81e-05	CbGpPWpGaD
